CN103270156B - Wdhd1肽及包含它们的疫苗 - Google Patents

Wdhd1肽及包含它们的疫苗 Download PDF

Info

Publication number
CN103270156B
CN103270156B CN201180060624.7A CN201180060624A CN103270156B CN 103270156 B CN103270156 B CN 103270156B CN 201180060624 A CN201180060624 A CN 201180060624A CN 103270156 B CN103270156 B CN 103270156B
Authority
CN
China
Prior art keywords
peptide
cancer
peptides
wdhd1
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180060624.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103270156A (zh
Inventor
中村佑辅
角田卓也
大泽龙司
吉村祥子
渡边朝久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN103270156A publication Critical patent/CN103270156A/zh
Application granted granted Critical
Publication of CN103270156B publication Critical patent/CN103270156B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
CN201180060624.7A 2010-10-21 2011-10-20 Wdhd1肽及包含它们的疫苗 Expired - Fee Related CN103270156B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40551710P 2010-10-21 2010-10-21
US61/405,517 2010-10-21
PCT/JP2011/005866 WO2012053206A1 (en) 2010-10-21 2011-10-20 Wdhd1 peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
CN103270156A CN103270156A (zh) 2013-08-28
CN103270156B true CN103270156B (zh) 2015-09-02

Family

ID=45974936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180060624.7A Expired - Fee Related CN103270156B (zh) 2010-10-21 2011-10-20 Wdhd1肽及包含它们的疫苗

Country Status (14)

Country Link
US (1) US9056890B2 (enExample)
EP (1) EP2630238A4 (enExample)
JP (1) JP2014504146A (enExample)
KR (1) KR20130138804A (enExample)
CN (1) CN103270156B (enExample)
AU (1) AU2011319359A1 (enExample)
BR (1) BR112013009526A2 (enExample)
CA (1) CA2815102A1 (enExample)
IL (1) IL225552A0 (enExample)
MX (1) MX2013004417A (enExample)
RU (1) RU2013123045A (enExample)
SG (1) SG189222A1 (enExample)
TW (1) TW201216982A (enExample)
WO (1) WO2012053206A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2663350C2 (ru) * 2012-09-11 2018-08-03 Онкотерапи Сайенс, Инк. Пептиды ube2t и содержащие их вакцины
CN114917189B (zh) 2017-01-25 2024-05-14 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116737A2 (en) * 2005-04-28 2006-11-02 Mcgill University Compounds and methods for modulating cadherin-mediated processes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
US20110160280A1 (en) 2007-08-24 2011-06-30 Oncotherapy Science, Inc. Cancer-related genes, cdca5, epha7, stk31 and wdhd1
US20100159513A1 (en) 2008-12-20 2010-06-24 E. I. Du Pont De Nemours And Compnay Genes that increase peptide production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116737A2 (en) * 2005-04-28 2006-11-02 Mcgill University Compounds and methods for modulating cadherin-mediated processes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis;N.SATO ET AL.;《CLINICAL CANCER RESEARCH》;20100101;第16卷(第1期);226-239 *

Also Published As

Publication number Publication date
US20130309259A1 (en) 2013-11-21
EP2630238A4 (en) 2014-02-19
AU2011319359A1 (en) 2013-05-02
TW201216982A (en) 2012-05-01
MX2013004417A (es) 2013-05-22
KR20130138804A (ko) 2013-12-19
EP2630238A1 (en) 2013-08-28
WO2012053206A1 (en) 2012-04-26
BR112013009526A2 (pt) 2017-05-02
US9056890B2 (en) 2015-06-16
CA2815102A1 (en) 2012-04-26
CN103270156A (zh) 2013-08-28
SG189222A1 (en) 2013-06-28
JP2014504146A (ja) 2014-02-20
RU2013123045A (ru) 2014-11-27
IL225552A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CN105164256B (zh) Kntc2肽及包含它们的疫苗
CN105601725B (zh) Neil3肽及包含它的疫苗
CN104066746B (zh) Topk肽及包含它们的疫苗
CN102947325B (zh) Cdca5肽及包含它们的疫苗
CN102822193B (zh) 修饰的melk肽及包含它们的疫苗
CN103732743B (zh) Mphosph1肽及包含它们的疫苗
CN104619833B (zh) Ube2t肽及包含它们的疫苗
CN103620033A (zh) Sema5b肽及包含它们的疫苗
CN102459314B (zh) Ttk肽及包含它们的疫苗
CN103339253B (zh) Tomm34肽及包含它们的疫苗
CN103189510B (zh) Ttll4肽及包含它们的疫苗
CN102939379B (zh) Ect2肽及包含它们的疫苗
CN102884190B (zh) Hjurp肽及包含它们的疫苗
CN102439147A (zh) Vangl1肽及包含它们的疫苗
CN103270156B (zh) Wdhd1肽及包含它们的疫苗
CN103282494B (zh) C18orf54肽及包含它们的疫苗
CN102770441A (zh) Tmem22肽及包含它们的疫苗
CN102753567A (zh) Mybl2肽及包含它们的疫苗
CN105814073A (zh) Sema5b肽和含有sema5b肽的疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150902

Termination date: 20161020

CF01 Termination of patent right due to non-payment of annual fee